Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Lung Cancer

Free Subscription 20.05.2019 1 Ann Oncol 3 Anticancer Res 4 BMC Cancer 1 BMJ 1 Cancer Cell 1 Cancer Res 4 Cancer Sci 2 Clin Cancer Res 1 Clin Lung Cancer 1 Eur Respir J 2 J Comput Assist Tomogr 1 J Natl Cancer Inst 2 J Thorac Oncol 2 JAMA Oncol 2 Lancet Respir Med 14 Lung Cancer 1 Nat Med 3 Nat Rev Cancer 2 Oncogene 2 PLoS One 3 Thorax

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Ann Oncol

1. HASTINGS K, Yu H, Wei W, Sanchez-Vega F, et al
   EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small cell lung cancer.
   Ann Oncol. 2019 May 14. pii: 5488949. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   

   
   Anticancer Res

2. KAIRA K, Imai H, Souma R, Sakurai R, et al
   An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer.
   Anticancer Res. 2019;39:2483-2491.
   PubMed     Text format     Abstract available
   
   
3. ERCAN S, Arinc S, Yilmaz SG, Altunok C, et al
   Investigation of Caspase 9 Gene Polymorphism in Patients With Non-small Cell Lung Cancer.
   Anticancer Res. 2019;39:2437-2441.
   PubMed     Text format     Abstract available
   
   
4. KAWACHI H, Fujimoto D, Yamashita D, Fukuoka J, et al
   Association Between Formalin Fixation Time and Programmed Cell Death Ligand 1 Expression in Patients With Non-Small Cell Lung Cancer.
   Anticancer Res. 2019;39:2561-2567.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

5. ZAHN MO, Linck D, Losem C, Gessner C, et al
   AVAiLABLE NIS - AVASTIN(R) in lung cancer treatment in routine oncology practice in Germany.
   BMC Cancer. 2019;19:433.
   PubMed     Text format     Abstract available
   
   
6. ZHAO F, Zhen FX, Zhou Y, Huang CJ, et al
   Clinicopathologic predictors of metastasis of different regional lymph nodes in patients intraoperatively diagnosed with stage-I non-small cell lung cancer.
   BMC Cancer. 2019;19:444.
   PubMed     Text format     Abstract available
   
   
7. VISSER S, Hou J, Bezemer K, de Vogel LL, et al
   Prediction of response to pemetrexed in non-small-cell lung cancer with immunohistochemical phenotyping based on gene expression profiles.
   BMC Cancer. 2019;19:440.
   PubMed     Text format     Abstract available
   
   
8. BAI H, Wang C, Qi Y, Xu J, et al
   Major vault protein suppresses lung cancer cell proliferation by inhibiting STAT3 signaling pathway.
   BMC Cancer. 2019;19:454.
   PubMed     Text format     Abstract available
   
   

   
   BMJ

9. JEBA J, Murray SA
   Palliative care: emphasis on early integration with oncology care.
   BMJ. 2019;365:l1974.
   PubMed     Text format    
   
   

   
   Cancer Cell

10. MORRIS LGT, Chan TA
    Lung Cancer Evolution: What's Immunity Got to Do with It?
    Cancer Cell. 2019;35:711-713.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Res

11. SONG M, Ping Y, Zhang K, Yang L, et al
    Low-dose IFN-gamma induces tumor cell stemness in the tumor microenvironment of non-small cell lung cancer.
    Cancer Res. 2019 May 13. pii: 0008-5472.CAN-19-0596.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Sci

12. HINO O, Abe M, Han B, Yan Y, et al
    In commemoration of the 2018 Mataro Nagayo Prize: A road to early diagnosis and monitoring of asbestos-related mesothelioma.
    Cancer Sci. 2019;110:1518-1524.
    PubMed     Text format     Abstract available
    
    
13. TU W, Yang B, Leng X, Pei X, et al
    Testis-specific protein, Y-linked 1 activates PI3K/AKT and RAS signaling pathways through suppressing IGFBP3 expression during tumor progression.
    Cancer Sci. 2019;110:1573-1586.
    PubMed     Text format     Abstract available
    
    
14. SUDO H, Tsuji AB, Sugyo A, Saga T, et al
    Therapeutic efficacy evaluation of radioimmunotherapy with (90) Y-labeled anti-podoplanin antibody NZ-12 for mesothelioma.
    Cancer Sci. 2019;110:1653-1664.
    PubMed     Text format     Abstract available
    
    
15. SONG L, Ma S, Chen L, Miao L, et al
    The long-term prognostic significance of IL-17 producing T cells in patients with non-small cell lung cancer.
    Cancer Sci. 2019 May 17. doi: 10.1111/cas.14068.
    PubMed     Text format     Abstract available
    
    

    
    Clin Cancer Res

16. THATCHER N, Goldschmidt JH, Thomas M, Schenker M, et al
    Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study.
    Clin Cancer Res. 2019;25:3193.
    PubMed     Text format    
    
    
17. FANG W, Ma Y, Yin JC, Hong S, et al
    Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small-Cell Lung Cancer.
    Clin Cancer Res. 2019 May 13. pii: 1078-0432.CCR-19-0585.
    PubMed     Text format     Abstract available
    
    

    
    Clin Lung Cancer

18. LI H, Verma V, Brooks ED, Feng L, et al
    Impact of Corticosteroid Administration on Outcomes Following Stereotactic Ablative Radiotherapy for Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2019 Mar 15. pii: S1525-7304(19)30074.
    PubMed     Text format     Abstract available
    
    

    
    Eur Respir J

19. GRACIE K, Kennedy MPT, Esterbrook G, Smith G, et al
    The proportion of lung cancer patients attending UK lung cancer clinics who would have been eligible for low-dose CT screening.
    Eur Respir J. 2019 May 16. pii: 13993003.02221-2018.
    PubMed     Text format    
    
    

    
    J Comput Assist Tomogr

20. YONGJUN J, Bingying Z, Taiping H, Yong Y, et al
    Effect of a New Model-Based Reconstruction Algorithm for Evaluating Early Peripheral Lung Cancer With Submillisievert Chest Computed Tomography.
    J Comput Assist Tomogr. 2019 May 6. doi: 10.1097/RCT.0000000000000858.
    PubMed     Text format     Abstract available
    
    
21. YONGJUN J, Bingying Z, Taiping H, Yong Y, et al
    Effect of a New Model-Based Reconstruction Algorithm for Evaluating Early Peripheral Lung Cancer With Submillisievert Chest Computed Tomography.
    J Comput Assist Tomogr. 2019;43:428-433.
    PubMed     Text format     Abstract available
    
    

    
    J Natl Cancer Inst

22. HUANG J, Weinstein SJ, Yu K, Mannisto S, et al
    A Prospective Study of Serum Vitamin E and 28-Year Risk of Lung Cancer.
    J Natl Cancer Inst. 2019 May 11. pii: 5488117. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    J Thorac Oncol

23. MUPPA P, Parrilha Terra SB, Sharma A, Mansfield AS, et al
    Immune Cell Infiltration May be a Key Determinant of Long-Term Survival in Small Cell Lung Cancer.
    J Thorac Oncol. 2019 May 9. pii: S1556-0864(19)30356.
    PubMed     Text format     Abstract available
    
    
24. TREMBLAY A, Taghizadeh N, Huang J, Kasowski D, et al
    A Randomized Controlled Study of Integrated Smoking Cessation in a Lung Cancer Screening Program.
    J Thorac Oncol. 2019 May 8. pii: S1556-0864(19)30359.
    PubMed     Text format     Abstract available
    
    

    
    JAMA Oncol

25. GIRI S, Huntington SF
    Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non-Small Cell Lung Cancer.
    JAMA Oncol. 2019 May 16. pii: 2733792. doi: 10.1001/jamaoncol.2019.1088.
    PubMed     Text format    
    
    
26. CRISS SD, Mooradian MJ, Kong CY
    Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non-Small Cell Lung Cancer-In Reply.
    JAMA Oncol. 2019 May 16. pii: 2733793. doi: 10.1001/jamaoncol.2019.1100.
    PubMed     Text format    
    
    

    
    Lancet Respir Med

27. TAYLOR SA, Mallett S, Ball S, Beare S, et al
    Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial.
    Lancet Respir Med. 2019 May 9. pii: S2213-2600(19)30090.
    PubMed     Text format     Abstract available
    
    
28. MEYER M, Budjan J
    Whole-body MRI for lung cancer staging: a step in the right direction.
    Lancet Respir Med. 2019 May 9. pii: S2213-2600(19)30081.
    PubMed     Text format    
    
    

    
    Lung Cancer

29. LIANG F, Wu C, Gu H, Zhu M, et al
    Lung cancer incidence in female rises significantly in urban sprawl of Shanghai after introduction of LDCT screening.
    Lung Cancer. 2019;132:114-118.
    PubMed     Text format     Abstract available
    
    
30. OYANAGI J, Koh Y, Sato K, Mori K, et al
    Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.
    Lung Cancer. 2019;132:107-113.
    PubMed     Text format     Abstract available
    
    
31. YOO JK, Lee JM, Kang SH, Jeon SH, et al
    The novel microRNA hsa-miR-CHA1 regulates cell proliferation and apoptosis in human lung cancer by targeting XIAP.
    Lung Cancer. 2019;132:99-106.
    PubMed     Text format     Abstract available
    
    
32. SUH CH, Kim KW, Pyo J, Hatabu H, et al
    The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis.
    Lung Cancer. 2019;132:79-86.
    PubMed     Text format     Abstract available
    
    
33. GALLI G, Triulzi T, Proto C, Signorelli D, et al
    Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer.
    Lung Cancer. 2019;132:72-78.
    PubMed     Text format     Abstract available
    
    
34. ASSOUN S, Theou-Anton N, Nguenang M, Cazes A, et al
    Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Lung Cancer. 2019;132:65-71.
    PubMed     Text format     Abstract available
    
    
35. ICHIHARA E, Hotta K, Ninomiya K, Kubo T, et al
    Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer.
    Lung Cancer. 2019;132:54-58.
    PubMed     Text format     Abstract available
    
    
36. CUI S, Ni Y, Zhao Y, Li Z, et al
    Epidermal growth factor receptor-targeted immunomagnetic liposomes for circulating tumor cell enumeration in non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors.
    Lung Cancer. 2019;132:45-53.
    PubMed     Text format     Abstract available
    
    
37. PLATANIA M, Pasini F, Porcu L, Boeri M, et al
    Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial.
    Lung Cancer. 2019;132:17-23.
    PubMed     Text format     Abstract available
    
    
38. VAD-NIELSEN J, Gammelgaard KR, Daugaard TF, Nielsen AL, et al
    Cause-and-Effect relationship between FGFR1 expression and epithelial-mesenchymal transition in EGFR-mutated non-small cell lung cancer cells.
    Lung Cancer. 2019;132:132-140.
    PubMed     Text format     Abstract available
    
    
39. WANG H, Agulnik J, Kasymjanova G, Fiset PO, et al
    The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma.
    Lung Cancer. 2019;132:36-38.
    PubMed     Text format     Abstract available
    
    
40. PARK K, Bennouna J, Boyer M, Hida T, et al
    Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.
    Lung Cancer. 2019;132:126-131.
    PubMed     Text format     Abstract available
    
    
41. MINNITI G, Scaringi C, Lanzetta G, Anzellini D, et al
    Comparative effectiveness of multi-fraction stereotactic radiosurgery for surgically resected or intact large brain metastases from non-small-cell lung cancer (NSCLC).
    Lung Cancer. 2019;132:119-125.
    PubMed     Text format     Abstract available
    
    
42. FUKUDA M, Kitazaki T, Ogawara D, Ichiki M, et al
    Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201).
    Lung Cancer. 2019;132:1-8.
    PubMed     Text format     Abstract available
    
    

    
    Nat Med

43. ABBOTT B
    Spreading the search.
    Nat Med. 2019;25:352-355.
    PubMed     Text format    
    
    

    
    Nat Rev Cancer

44. BARATTA MG
    To be (immunosuppressive) or not to be.
    Nat Rev Cancer. 2019;19:181.
    PubMed     Text format    
    
    
45. DART A
    Microbiota and immune cell interplay.
    Nat Rev Cancer. 2019;19:182.
    PubMed     Text format    
    
    
46. HINDSON J
    Radiation promotes systemic responses.
    Nat Rev Cancer. 2019;19:4-5.
    PubMed     Text format    
    
    

    
    Oncogene

47. WANG C, Gu Y, Zhang E, Zhang K, et al
    A cancer-testis non-coding RNA LIN28B-AS1 activates driver gene LIN28B by interacting with IGF2BP1 in lung adenocarcinoma.
    Oncogene. 2019;38:1611-1624.
    PubMed     Text format     Abstract available
    
    
48. HSU FF, Chou YT, Chiang MT, Li FA, et al
    Signal peptide peptidase promotes tumor progression via facilitating FKBP8 degradation.
    Oncogene. 2019;38:1688-1701.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

49. STANZE H, Schneider N, Nauck F, Marx G, et al
    "I can't get it into my head that I have cancer..."-A qualitative interview study on needs of patients with lung cancer.
    PLoS One. 2019;14:e0216778.
    PubMed     Text format     Abstract available
    
    
50. HU ZG, Hu K, Li WX, Zeng FJ, et al
    Prognostic factors and nomogram for cancer-specific death in non small cell lung cancer with malignant pericardial effusion.
    PLoS One. 2019;14:e0217007.
    PubMed     Text format     Abstract available
    
    

    
    Thorax

51. STEINER MC
    Should pulmonary rehabilitation be a standard of care in lung cancer?
    Thorax. 2019 May 15. pii: thoraxjnl-2019-213157.
    PubMed     Text format    
    
    
52. PEZZELLA F
    Early squamous cell lung carcinoma: prognostic biomarkers for the many.
    Thorax. 2019;74:527-528.
    PubMed     Text format    
    
    
53. ZHANG S, Zhang S, Zhang W, He J, et al
    Pulmonary inflammatory myofibroblastic tumour and IgG4-related disease presenting with lower limb paralysis.
    Thorax. 2019;74:313-314.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: